Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

NovoLet® Surveillance Study on Using Human Insulin System in Indonesia

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2

Interventions: Drug: biphasic human insulin
Drug: isophane human insulin
Drug: human soluble insulin

First Posted Date: 2011-12-14

Last Posted Date: 2017-02-28

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1981

Registration Number: NCT01492153

Locations: 🇮🇩
Novo Nordisk Investigational Site, Jakarta, Indonesia

NovoLet® Acceptance Study Within the Hospital Practise in Indonesia

Completed

Conditions: Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: insulin human

First Posted Date: 2011-12-14

Last Posted Date: 2016-10-14

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 203

Registration Number: NCT01492205

Locations: 🇮🇩
Novo Nordisk Investigational Site, Jakarta, Indonesia

Observational Study on Efficacy, Safety and Convenience of Using Mixtard® 30 NovoLet® Alone or Combined With OHA in Treatment of Type 2 Diabetes in Routine Clinical Practice

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: biphasic human insulin 30

First Posted Date: 2011-12-14

Last Posted Date: 2016-12-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1935

Registration Number: NCT01492166

Locations: 🇮🇩
Novo Nordisk Investigational Site, Jakarta, Indonesia

Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Fed Healthy Volunteers

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: repaglinide
Drug: metformin
Drug: repaglinide and metformin combination tablet

First Posted Date: 2011-12-13

Last Posted Date: 2017-02-10

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 93

Registration Number: NCT01490658

Locations: 🇺🇸
Novo Nordisk Investigational Site, Austin, Texas, United States

Surveillance Study of NovoRapid® for New Drug Re-examination

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2

Interventions: Drug: insulin aspart

First Posted Date: 2011-12-12

Last Posted Date: 2016-10-28

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1239

Registration Number: NCT01490112

Locations: 🇰🇷
Novo Nordisk Investigational Site, Seoul, Korea, Republic of

Comparison of Insulin Detemir Produced by the Current Process and the NN729 Process in Healthy Subjects

Phase 1

Completed

Conditions: Healthy
Diabetes

Interventions: Drug: insulin detemir

First Posted Date: 2011-12-12

Last Posted Date: 2016-02-08

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 37

Registration Number: NCT01490099

Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Healthy Volunteers

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: repaglinide
Drug: metformin
Drug: repaglinide and metformin combination tablet

First Posted Date: 2011-12-09

Last Posted Date: 2017-02-10

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 62

Registration Number: NCT01489644

Locations: 🇺🇸
Novo Nordisk Investigational Site, Tacoma, Washington, United States

Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A.

Phase 3

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A

Interventions: Drug: turoctocog alfa pegol

First Posted Date: 2011-12-09

Last Posted Date: 2020-08-10

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 36

Registration Number: NCT01489111

Locations: 🇬🇧
Novo Nordisk Investigational Site, Sheffield, United Kingdom

Comparison of Insulin Detemir Plus Insulin Aspart With Insulin NPH Plus Human Soluble Insulin in Subjects With Type 1 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: insulin NPH
Drug: insulin detemir
Drug: human soluble insulin
Drug: insulin aspart

First Posted Date: 2011-12-07

Last Posted Date: 2017-01-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 598

Registration Number: NCT01486940

Locations: 🇸🇪
Novo Nordisk Investigational Site, Falun, Sweden

Bioequivalence of Two Mixtard® 30 Formulations in Healthy Subjects

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: biphasic human insulin 30

First Posted Date: 2011-12-07

Last Posted Date: 2015-03-18

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 45

Registration Number: NCT01486888

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy